Astatine 211
No carrier added
IONETIX produces Astatine-211 in the Lansing, Michigan facility. Astatine-211 is currently considered as one of the most promising alpha particle emitters for application in targeted alpha therapy (TAT) of cancers (Eychenne et al. 2021), a modality that is experiencing an increasing interest and is expected to have a strong impact on cancer treatment in the coming years (Jang et al. 2023; Miederer et al. 2024).1
1 Vanermen, M., Ligeour, M., Oliveira, MC. et al. Astatine-211 radiolabelling chemistry: from basics to advanced biological applications. EJNMMI radiopharm. chem. 9, 69 (2024). https://doi.org/10.1186/s41181-024-00298-4
Learn more about Alpha Therapy→
A centrally located isotope manufacturing facility located in Lansing, Michigan
This first-of-kind facility is dedicated exclusively to producing the alpha-emitting isotopes Ac-225 and At-211, leveraging our cyclotron and accelerator expertise. The company completed the installation and commissioning of the first cyclotron at the Lansing facility in 2023. A second cyclotron is expected to be commissioned in late 2026, adding both scalable supply capacity and onsite production redundancy. A second site at another US location is in development.
Harness the power to deliver advanced radiopharmaceuticals
The time is now to partner with us to gain access to scarce diagnostics and therapeutic radiopharmaceuticals.
Get started now→